Prognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome

Journal of Dermatological Science

Volumn 57, Issue 1, 2010, Pages 37-43

  Suzuki, Shin ya ^a   Ito, Kaoru ^a,b   Ito, Masaaki ^a   Kawai, Kazuhiro ^a,c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NAGAOKA RED CROSS HOSPITAL   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cutaneous T cell lymphoma; Mycosis fungoides; Prognosis; S zary syndrome

Indexed keywords

CORTICOSTEROID; ETRETINATE; GAMMA INTERFERON; PSORALEN;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; EUROPE; FEMALE; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PHOTOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEZARY SYNDROME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNITED STATES; UNIVERSITY HOSPITAL;

AGED; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; LYMPH NODES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; PROGNOSIS; RETROSPECTIVE STUDIES; SEZARY SYNDROME;

EID: 72149096517     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.10.010     Document Type: Article

References (52)

1. Ralfkiaer E., Cerroni L., Sander C.A., Smoller B.R., and Willemze R. Mycosis fungoides. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), IARC, Lyon 296-298
2. Ralfkiaer E., Willemze R., and Whittaker S.J. Sézary syndrome. In: Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., and Vardiman J.W. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), IARC, Lyon p. 299
3. Green S.B., Byar D.P., and Lamberg S.I. Prognostic variables in mycosis fungoides. Cancer 47 (1981) 2671-2677
4. Lamberg S.I., Green S.B., Byar D.P., Block J.B., Clendenning W.E., Douglas M.C., et al. Clinical staging for cutaneous T-cell lymphoma. Ann Intern Med 100 (1984) 187-192
5. Sausville E.A., Worsham G.F., Matthews M.J., Makuch R.W., Fischmann A.B., Schechter G.P., et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 16 (1985) 1098-1109
6. Schechter G.P., Sausville E.A., Fischmann A.B., Soehnlen F., Eddy J., Matthews M., et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 69 (1987) 841-849
7. Sausville E.A., Eddy J.L., Makuch R.W., Fischmann A.B., Schechter G.P., Matthews M., et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 109 (1988) 372-382
8. Merlo C.J., Hoppe R.T., Abel E., and Cox R.S. Extracutaneous mycosis fungoides. Cancer 60 (1987) 397-402
9. Marti R.M., Estrach T., Reverter J.C., and Mascaro J.M. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 127 (1991) 1511-1516
10. Kim Y.H., Bishop K., Varghese A., and Hoppe R.T. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 131 (1995) 1003-1008
11. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., and Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (2003) 857-866
12. Hoppe R.T., Medeiros L.J., Warnke R.A., and Wood G.S. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32 (1995) 448-453
13. Wasik M.A., Vonderheid E.C., Bigler R.D., Marti R., Lessin S.R., Polansky M., et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma: clinical and prognostic implications. Arch Dermatol 132 (1996) 42-47
14. Toro J.R., Stoll Jr. H.L., Stomper P.C., and Oseroff A.R. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 37 (1997) 58-67
15. Vonderheid E.C., Ekbote S.K., Kerrigan K., Kalmanson J.D., Van Scott E.J., Rook A.H., et al. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. J Invest Dermatol 110 (1998) 946-950
16. Vonderheid E.C., Pena J., and Nowell P. Sézary cell counts in erythrodermic cutaneous T-cell lymphoma: implications for prognosis and staging. Leuk Lymphoma 47 (2006) 1841-1856
17. Diamandidou E., Colome M., Fayad L., Duvic M., and Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 40 (1999) 914-924
18. Zackheim H.S., Amin S., Kashani-Sabet M., and McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (1999) 418-425
19. Weinstock M.A., and Reynes J.F. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 85 (1999) 208-212
20. van Doorn R., Van Haselen C.W., van Voorst Vader P.C., Geerts M.L., Heule F., de Rie M., et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 136 (2000) 504-510
21. Vergier B., de Muret A., Beylot-Barry M., Vaillant L., Ekouevi D., Chene G., et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 95 (2000) 2212-2218
22. Fraser-Andrews E.A., Woolford A.J., Russell-Jones R., Seed P.T., and Whittaker S.J. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 114 (2000) 117-121
23. Fraser-Andrews E.A., Mitchell T., Ferreira S., Seed P.T., Russell-Jones R., Calonje E., et al. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides. Br J Dermatol 155 (2006) 756-762
24. Scarisbrick J.J., Whittaker S., Evans A.V., Fraser-Andrews E.A., Child F.J., Dean A., et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 97 (2001) 624-630
25. Foulc P., N'Guyen J.M., and Dreno B. Prognostic factors in Sézary syndrome: a study of 28 patients. Br J Dermatol 149 (2003) 1152-1158
26. Klemke C.D., Mansmann U., Poenitz N., Dippel E., and Goerdt S. Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome. Br J Dermatol 153 (2005) 118-124
27. Juarez T., Isenhath S.N., Polissar N.L., Sabath D.E., Wood B., Hanke D., et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 141 (2005) 1107-1113
28. + lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 153 (2005) 324-330
29. Morales M.M., Putcha V., Evans H.S., Olsen J., Llopis A., and Moller H. Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 211 (2005) 325-329
30. Vidulich K.A., Talpur R., Bassett R.L., and Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 48 (2009) 243-252
31. Bunn Jr. P.A., and Lamberg S.I. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 63 (1979) 725-728
32. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (2007) 1713-1722
33. Sun G., Berthelot C., Li Y., Glass Jr. D.A., George D., Pandya A., et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 60 (2009) 231-235
34. Pimpinelli N., Olsen E.A., Santucci M., Vonderheid E., Haeffner A.C., Stevens S., et al. Defining early mycosis fungoides. J Am Acad Dermatol 53 (2005) 1053-1063
35. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
36. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
37. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
38. Cox D.R. Regression models and life tables. J R Stat Soc (B) 34 (1972) 187-220
39. Wright S.P. Adjusted p-values for simultaneous inferences. Biometrics 48 (1992) 1005-1013
40. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
41. Vonderheid E.C., Bernengo M.G., Burg G., Duvic M., Heald P., Laroche L., et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46 (2002) 95-106
42. Marti R.M., Pujol R.M., Servitje O., Palou J., Romagosa V., Bordes R., et al. Sézary syndrome and related variants of classic cutaneous T-cell lymphoma: a descriptive and prognostic clinicopathologic study of 29 cases. Leuk Lymphoma 44 (2003) 59-69
43. Schmid M.H., Bird P., Dummer R., Kempf W., and Burg G. Tumor burden index as a prognostic tool for cutaneous T-cell lymphoma: a new concept. Arch Dermatol 135 (1999) 1204-1208
44. 2) mycosis fungoides. Arch Dermatol 135 (1999) 26-32
45. Bernengo M.G., Quaglino P., Novelli M., Cappello N., Doveil G.C., Lisa F., et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 9 (1998) 857-863
46. Vonderheid E.C., Zhang Q., Lessin S.R., Polansky M., Abrams J.T., Bigler R.D., et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 38 (1998) 207-220
47. Hassel J.C., Meier R., Joller-Jemelka H., Burg G., and Dummer R. Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 209 (2004) 296-300
48. A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
49. Kim Y.H., Jensen R.A., Watanabe G.L., Varghese A., and Hoppe R.T. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol 132 (1996) 1309-1313
50. Berkson J., and Gage R.P. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin 25 (1950) 270-286
51. Cancer survival analysis. In: Green F.L., Page D.L., Fleming I.D., Fritz A.G., Balch C.M., Haller D.G., and Morrow M. (Eds). AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, New York 9-15
52. de Coninck E.C., Kim Y.H., Varghese A., and Hoppe R.T. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19 (2001) 779-784